Cargando…
Hepatitis C Virus (HCV)–Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design
With more than 71 million people chronically infected, hepatitis C virus (HCV) is one of the leading causes of liver disease and hepatocellular carcinoma. While efficient antiviral therapies have entered clinical standard of care, the development of a protective vaccine is still elusive. Recent stud...
Autores principales: | Wrensch, Florian, Crouchet, Emilie, Ligat, Gaetan, Zeisel, Mirjam B., Keck, Zhen-Yong, Foung, Steven K. H., Schuster, Catherine, Baumert, Thomas F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021501/ https://www.ncbi.nlm.nih.gov/pubmed/29977246 http://dx.doi.org/10.3389/fimmu.2018.01436 |
Ejemplares similares
-
Host-targeting therapies for hepatitis C virus infection: current developments and future applications
por: Crouchet, Emilie, et al.
Publicado: (2018) -
Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017) -
Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine
por: Keck, Mei-Le, et al.
Publicado: (2018) -
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection
por: Zeisel, Mirjam B., et al.
Publicado: (2015) -
Syndecan 4 Is Involved in Mediating HCV Entry through Interaction with Lipoviral Particle-Associated Apolipoprotein E
por: Lefèvre, Mathieu, et al.
Publicado: (2014)